Literature DB >> 16859898

Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients?

Victoria Villalta-Gil1, Míriam Vilaplana, Susana Ochoa, Josep Maria Haro, Montserrat Dolz, Judit Usall, Jorge Cervilla.   

Abstract

OBJECTIVE: The aim of this study is to assess if cognitive variables and symptom dimensions can predict disability in a sample of outpatients with schizophrenia.
METHOD: A cross-sectional sample of 113 individuals with a diagnosis of schizophrenia (DSM-IV criteria) was selected from a computerized register of five Community Mental Health Centers. Patients were assessed by two trained psychologists, with a neuropsychological battery comprising measures for verbal memory, attention, operative memory and abstraction and flexibility functions. Symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS); a socio-demographic and clinical questionnaire, comprising the Disability Assessment Scale (DAS), was also completed. Test scores were standardized (t scores) to performance of healthy controls. To assess the relationship between clinical and sociodemographic factors and disability and cognitive functioning Pearson's correlation coefficients were computed. In order to establish the predictive capacity of the cognitive, clinical and symptom variables on disability linear regression models were fitted.
RESULTS: Mean age of patients was 41.6 years and 68% were male. Higher ratings in the negative dimension were associated with more cognitive deficits. Association with the positive dimension was present but less strong. All disability areas, except for disability in occupational functioning, were partially explained by the negative dimension. Disability in family functioning was also partially explained by attention and number of admissions since onset.
CONCLUSION: Negative symptoms are the major source of disability of our sample and are also associated to cognitive functioning. The present findings suggest that further investigation on the mediators between clinical and social outcomes may help to design specific treatments to reduce disability.

Entities:  

Mesh:

Year:  2006        PMID: 16859898     DOI: 10.1016/j.schres.2006.06.013

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  22 in total

1.  Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits.

Authors:  Joseph Ventura; April D Thames; Rachel C Wood; Lisa H Guzik; Gerhard S Hellemann
Journal:  Schizophr Res       Date:  2010-06-25       Impact factor: 4.939

2.  Less unique variance than meets the eye: overlap among traditional neuropsychological dimensions in schizophrenia.

Authors:  Dwight Dickinson; James M Gold
Journal:  Schizophr Bull       Date:  2007-08-16       Impact factor: 9.306

Review 3.  Asenapine: A Review in Schizophrenia.

Authors:  Greg L Plosker; Emma D Deeks
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

4.  Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.

Authors:  Simon Zhornitsky; Emmanuel Stip; Joelle Desfossés; Tania Pampoulova; Elie Rizkallah; Pierre-Paul Rompré; Lahcen Aït Bentaleb; Olivier Lipp; Jean-Pierre Chiasson; Alain Gendron; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2011-05-13       Impact factor: 4.157

5.  Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis.

Authors:  Chuan Shi; Xin Yu; Eric F C Cheung; David H K Shum; Raymond C K Chan
Journal:  Psychiatry Res       Date:  2013-12-21       Impact factor: 3.222

6.  Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.

Authors:  Camilo de la Fuente-Sandoval; Pablo León-Ortiz; Rafael Favila; Sylvana Stephano; David Mamo; Jesús Ramírez-Bermúdez; Ariel Graff-Guerrero
Journal:  Neuropsychopharmacology       Date:  2011-04-20       Impact factor: 7.853

7.  Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis.

Authors:  Joseph Ventura; Gerhard S Hellemann; April D Thames; Vanessa Koellner; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2009-07-22       Impact factor: 4.939

8.  Physical activity level and medial temporal health in youth at ultra high-risk for psychosis.

Authors:  Vijay A Mittal; Tina Gupta; Joseph M Orr; Andrea Pelletier-Baldelli; Derek J Dean; Jessica R Lunsford-Avery; Ashley K Smith; Briana L Robustelli; Daniel R Leopold; Zachary B Millman
Journal:  J Abnorm Psychol       Date:  2013-11

9.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.

Authors:  Paolo Fusar-Poli; Evangelos Papanastasiou; Daniel Stahl; Matteo Rocchetti; William Carpenter; Sukhwinder Shergill; Philip McGuire
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

10.  The magnitude of disability in patients with schizophrenia in North West Ethiopia: A multicenter hospital-based cross-sectional study.

Authors:  Getnet Mihretie Beyene; Getasew Legas; Telake Azale; Mebrat Abera; Sintayehu Asnakew
Journal:  Heliyon       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.